MEDiC

MEDiC Life Sciences is a biotechnology company that develops CRISPR-based cancer organoids for clinical trial research and drug development. The company has incorporated genome-scale CRISPR/Cas9 functional genomics tools into 3D cancer organoids based on specific cancer types, enabling systematic recapitulation of genetic mutations found in tumors. MEDiC proprietary tumor-immune co-culture system integrated with CRISPR technology allows researchers to precisely assess the functional contribution of cancer mutations for tumor growth, immune response, and drug response, identifying biomarkers, synthetic lethality, and resistant mutations for novel cancer drug development. The platform addresses the gap in current drug development systems that miss potential biomarkers and novel drug targets by combining the power of CRISPR functional genomics with the accuracy and translatability of patient tumor-like cancer models. Founded in 2019 and headquartered in San Carlos, California, MEDiC has raised $13 million in seed funding from investors including Hanmi Pharmaceuticals, LG Chem, Illumina, Top Harvest Capital, and Wing Venture Capital.